Search

Resumen Introduccion El estudio de vellosidades coriales comprende realizar 2 cultivos celulares que pueden no tener resultados coincidentes. Estas discrepancias pueden ser debidas a mosaicos citogeneticos de origen in vivo o in vitro . En este trabajo nos planteamos analizar los cariotipos en mosaicos, ligado con los rendimientos de los cultivos celulares y los resultados citogeneticos. Material y metodos Se han analizado 2.360 muestras prenatales y 510 de vellosidades de abortos. Con las muestras prenatales se efectuan rutinariamente 2 cultivos celulares, cultivo corto y cultivo largo, y para los abortos ademas se han estudiado muestras de restos fetales. Resultados El porcentaje de muestras con resultado citogenetico para el grupo prenatal fue del 99,9% y para el grupo de abortos del 87,1%. El porcentaje de anomalias cromosomicas en el grupo prenatal fue del 10,6% siendo las aneuploidias comunes (trisomias 13, 18, y 21) las mas frecuentes, y para el grupo de abortos fue del 55,1% siendo las aneuploidias no-comunes las mas frecuentes. El porcentaje de cariotipos en mosaico para el grupo prenatal fue del 3,1% y para el grupo de abortos del 6,8%. El mosaico confinado a la placenta tipo ii fue el mas frecuente. Conclusiones Para el estudio de los mosaicos en vellosidades coriales la mejor estrategia es realizar los 2 cultivos paralelos en muestras prenatales y los 3 cultivos en muestras de abortos. Teniendo en cuenta el riesgo que asume la pareja ante una prueba invasiva, es nuestro deber dar el resultado citogenetico mas completo posible.

The excess of genetic information in patients with Down syndrome (DS) produces an increase in the catalytic activity of superoxide dismutase (SOD1), an antioxidant enzyme coded on chromosome 21. It has been suggested that an increase in oxidative stress in DS patients may cause adverse effects in the cell membranes through the oxidation of polyunsaturated fatty acids (PUFAs). The aim of this study was to evaluate the cellular antioxidant system by determining the catalytic activity of the SOD1, glutathione peroxidase (GPx), catalase (CAT), and glutathione reductase (GR) enzymes and the concentrations of α-tocopherol in red blood cells (RBCs) in a group of 72 DS patients. The profile of fatty acids in the phospholipids of RBC membranes was also evaluated. The activity of the erythrocyte antioxidant enzymes is significantly higher in the DS group than in the control group (SOD1, 635 ± 70 U/g Hb vs 476 ± 67 U/g Hb; CAT, 1843 ± 250 U/g Hb vs 1482 ± 250 U/g Hb; GPx, 23.2 ± 5.3 U/g Hb vs 21.5 ± 3.6 U/g Hb; and GR, 9.32 ± 1.4 U/g Hb vs 6.9 ± 1.3 U/g Hb, respectively). No differences were observed in RBC α-tocopherol concentrations between the two groups studied. Long-chain n6 PUFA (C20:3n6, C20:4n6) concentrations were increased in DS patients, suggesting enhanced Δ-6-desaturase activity. The long-chain n3 PUFA (docosahexenoic acid) does not appear to be affected by increased oxidative stress, probably because of the existence of compensatory antioxidant mechanisms.

To assess the potential value of ductus venosus Doppler studies in the detection of fetal aneuploidy on measurement of nuchal translucency.The pulsatility index for veins (PIV) and the lowest velocity during atrial contraction (A-wave) were determined in the fetal ductus venosus in 3382 consecutive pregnancies at 10 to 14 weeks and studied from December 1996 to December 2001. Nuchal translucency was also measured. The population studied included 1664 pregnancies at high risk and 1718 at low risk for fetal aneuploidy.In relation to the prenatal detection of trisomy 21, the ductus venosus PIV was increased in 75% (36/48), the A-wave was decreased in 58% (28/48), and nuchal translucency was enlarged in 81% (39/48) of the trisomy 21 fetuses [71% (22/31) when nuchal translucency referrals were excluded]. The corresponding figures for trisomies 18 and 13 were 71, 58 and 83%, respectively, being 33, 33 and 33% for other unbalanced anomalies.There is a high proportion of fetuses with trisomies 21, 18 and 13 (around 75%) in which the ductus venosus PIV is increased (above the 95th percentile) at 10 to 14 weeks, this proportion being similar to that observed for increased nuchal translucency measurement.